Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$12.41 USD
+0.72 (6.16%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.40 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
STOK 12.41 +0.72(6.16%)
Will STOK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
Other News for STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer
Buy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioning
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haleon PLC (GB:HLN) and Stoke Therapeutics (STOK)
12 Health Care Stocks Moving In Friday's After-Market Session